Chinese company accused of lying to FDA inspectors

FDA sign

Most drug manufacturers respond immediately to the FDA after having their plant operations criticized in an inspection. Not China’s Xiamen Origin Biotech. It hasn’t responded about the inspection at all.

Oh, the Fujian-based operator did contact the FDA about the fact that its API products had been put on an import alert list in May, but about the January inspection that led to its products being banned, and now to a warning letter from the FDA, the agency says it has not heard word one.

According to the warning letter that the FDA posted this week, Xiamen Origin Biotech has big problems. It has no written procedures for how to handle all of the basic requirements, supplier qualification, sampling, product release, training, labeling, or document retention. It was unable to produce one record for its labeling operations going back 18 months.  


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

The company also tried to delay and mislead inspectors, the warning letter says, telling them there were no drugs at the facility even though there was clearly a warehouse at the site. Employees also denied the company was relabeling APIs any longer, the FDA said, despite evidence that it sold relabeled products throughout 2015 and into 2016.

On top of that, the company repeatedly falsified and omitted information on the certificates of analysis (CoA) sent to customers, the FDA said. It fabricated the name of an employee, then used the fake name as “the false signatory authority on the CoA,” the FDA said.

The warehouse was dirty and a rodent was seen in a room next to it.

The FDA suggested that Xiamen Origin get a consultant to learn how business is done with the U.S. It pointed out to owner Zhang Jian that the company can expect to remain on the FDA’s import alert list, and its products prohibited from coming into the U.S., until the company responds and fixes its issues.  

The warning is one among a series sent to Chinese drug manufacturers in recent weeks, as the FDA steps up its oversight of a rapidly growing API exporter.

- here’s the warning letter

Related Articles: 
FDA warnings slam Chinese drugmakers, including ViiV partner 
Chinese API maker spanked in warning letter 
Issues at Chinese API maker undermine Lannett drug approval


Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.